WebFeb 22, 2024 · On January 19, Scandion receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101. … WebFeb 24, 2024 · Scandion’s Q422 and FY22 results highlighted the significance of the upcoming year, with key clinical milestones expected for its lead asset SCO-101. The first of these comes in the form of top-line readouts from the Phase Ib PANTAX study in pancreatic cancer (PC), which is expected in H123. These will be closely followed by top-line results …
Scandion Oncology A/S - Cision
WebFounded Date 2024. Founders Jan Stenvang. Operating Status Active. Last Funding Type Grant. Company Type For Profit. Contact Email [email protected]. Phone Number +45 38 10 20 17. Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for … WebFeb 4, 2024 · Scandion Oncology aktie (SCOL) – Nyheter, aktiekurs, analys, riktkurs och mycket mer. På den här sidan samlar vi en stor mängd information om bolaget/aktien … indian river batteries vero beach fl
Scandion Oncology - Annual Report 2024 MarketScreener
WebApr 3, 2024 · Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the … WebScandion Oncology har uppnått det primära målet i fas Ib-studien PANTAX – att identifiera maximalt tolererad dos av läkemedelskandidaten SCO-101 i patienter med avancerad pankreascancer. Kandidaten visade sig även vara säker och väl tolererad. WebJan 12, 2024 · Scandion Oncology - Positive outlook for SCO-101. 315. Edison Investment Research. Scandion Oncology is approaching a major inflection point as results from the … indian river basins